How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
Is deferring chemotherapy based on low oncotype acceptable in setting of recurrence?
Would you recommend using a different AI, Tamoxifen, or Fulvestrant as endocrine therapy if Exemestane was used for initial breast cancer 3 years ago?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on
The question does not provide the details of recurrence as to whether this is a locoregional breast recurrence, with or without lymph node or chest wall involvement. Ipsilateral or contralateral or second primary? Prior lumpectomy margins, prior type, and extent of radiation therapy? Time to recurre...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Banner MD Anderson Cancer Center
Answered on
In the CALOR trial that studied chemo vs. no chemo after resection of isolated locoregional recurrence, there is benefit of adjuvant chemotherapy. The 5-year HR for DFS with chemo was 0.59. The 5-year HR for OS with chemo was 0.41. The benefit was mainly seen in HR- patients. This patient has a very...
Join for free or sign in to see the full answer